A053030 Stock Overview
Operates as a pharmaceutical company in South Korea. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
BINEX Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩16,260.00 |
52 Week High | ₩27,300.00 |
52 Week Low | ₩7,710.00 |
Beta | 0.51 |
11 Month Change | -21.07% |
3 Month Change | -31.68% |
1 Year Change | 101.99% |
33 Year Change | 4.57% |
5 Year Change | 112.55% |
Change since IPO | 755.79% |
Recent News & Updates
BINEX Co., Ltd. (KOSDAQ:053030) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Nov 18Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?
Oct 23Revenues Not Telling The Story For BINEX Co., Ltd. (KOSDAQ:053030) After Shares Rise 25%
Sep 01Subdued Growth No Barrier To BINEX Co., Ltd. (KOSDAQ:053030) With Shares Advancing 32%
Jul 01Recent updates
BINEX Co., Ltd. (KOSDAQ:053030) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Nov 18Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?
Oct 23Revenues Not Telling The Story For BINEX Co., Ltd. (KOSDAQ:053030) After Shares Rise 25%
Sep 01Subdued Growth No Barrier To BINEX Co., Ltd. (KOSDAQ:053030) With Shares Advancing 32%
Jul 01BINEX Co., Ltd.'s (KOSDAQ:053030) 30% Share Price Plunge Could Signal Some Risk
Apr 17We Think That There Are More Issues For BINEX (KOSDAQ:053030) Than Just Sluggish Earnings
Mar 22BINEX Co., Ltd.'s (KOSDAQ:053030) Shares Climb 37% But Its Business Is Yet to Catch Up
Feb 26Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?
Mar 18If You Had Bought BINEX (KOSDAQ:053030) Stock A Year Ago, You Could Pocket A 253% Gain Today
Jan 28Are BINEX Co., Ltd.'s (KOSDAQ:053030) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Dec 24Shareholder Returns
A053030 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | -12.1% | -3.1% | 2.9% |
1Y | 102.0% | 4.8% | -2.8% |
Return vs Industry: A053030 exceeded the KR Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: A053030 exceeded the KR Market which returned -2.8% over the past year.
Price Volatility
A053030 volatility | |
---|---|
A053030 Average Weekly Movement | 11.5% |
Pharmaceuticals Industry Average Movement | 5.2% |
Market Average Movement | 5.6% |
10% most volatile stocks in KR Market | 11.6% |
10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A053030's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A053030's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1957 | 552 | Hyuk-Jong Lee | www.bi-nex.co.kr |
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. The company engages in cell line and process development, and analytical method production development. It is also involved in cell cultivation and microbial fermentation modalities process production.
BINEX Co., Ltd. Fundamentals Summary
A053030 fundamental statistics | |
---|---|
Market cap | ₩517.84b |
Earnings (TTM) | -₩18.86b |
Revenue (TTM) | ₩128.30b |
4.0x
P/S Ratio-27.5x
P/E RatioIs A053030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A053030 income statement (TTM) | |
---|---|
Revenue | ₩128.30b |
Cost of Revenue | ₩101.86b |
Gross Profit | ₩26.44b |
Other Expenses | ₩45.30b |
Earnings | -₩18.86b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -592.18 |
Gross Margin | 20.61% |
Net Profit Margin | -14.70% |
Debt/Equity Ratio | 35.2% |
How did A053030 perform over the long term?
See historical performance and comparison